AUS
NZ
UK
CA
USA
IND
On July 27, 2026, ARCpoint Inc. (TSXV:ARC), a healthcare technology firm, revealed that the British Columbia Securities Commission (BCSC) has denied its application for a management cease trade order (MCTO). The regulator warned that a failure-to-file cease trade order (FFCTO) will likely be imposed if the company does not submit its annual financial statements by the July 29, 2026 deadline. ARCpoint attributed the anticipated delay to insufficient financial resources to complete its audit and compensate auditors.
Key Highlights
- ARCpoint Inc. (TSXV:ARC) provided a regulatory update concerning its annual financial statement filing requirements.
- The BCSC rejected ARCpoint's MCTO application due to inadequate financial means to resolve the filing default.
- An FFCTO is expected if annual financial statements for the fiscal year ending March 31, 2026, remain unfiled by July 29, 2026.
- The FFCTO would halt all trading of ARCpoint securities on the TSX Venture Exchange until filings are completed and the order lifted.
BCSC Denies ARCpoint’s Management Cease Trade Order Request
According to ARCpoint’s July 27, 2026 announcement, the British Columbia Securities Commission declined the company’s application for a management cease trade order under National Policy 12-203. This application followed ARCpoint’s July 15, 2026 disclosure anticipating a missed annual filing deadline.
The BCSC stated that ARCpoint lacks the necessary financial resources to correct the filing default as required by section 6(c) of National Policy 12-203. Despite ongoing efforts, ARCpoint has not secured funding to the regulator’s satisfaction.
Impending Failure-to-File Cease Trade Order and Market Impact
The BCSC has warned that if ARCpoint fails to file its annual financial statements by July 29, 2026, a failure-to-file cease trade order will be issued. Unlike an MCTO, which restricts trading only by management and insiders, an FFCTO broadly suspends trading for all shareholders and market participants.
Should the FFCTO be enacted, all trading of ARCpoint securities, including on the TSX Venture Exchange, would be prohibited until the audited statements and related documents are filed and the order revoked. The BCSC will determine the terms and any exceptions of the FFCTO upon issuance.
Filing Delay Driven by Funding Shortfall
ARCpoint attributed the delay in completing its annual financial statements to a lack of funds to pay auditors and accounting staff responsible for the audit and filings. The required documents include the annual financial statements, management’s discussion and analysis, and CEO and CFO certificates for the year ended March 31, 2026.
The company continues efforts to secure necessary financing but has not yet met the BCSC’s requirements. Consequently, ARCpoint expects it will miss the July 29 filing deadline and anticipates the issuance of an FFCTO.
Critical Filing Deadline and Future Updates
The July 29, 2026 deadline is pivotal for ARCpoint’s regulatory compliance. Failure to meet this date will likely trigger the BCSC’s automatic issuance of an FFCTO.
ARCpoint stated it is working to file the statements as soon as possible and will announce a revised filing date when feasible. The company will continue providing updates via news releases as required under Canadian securities laws. Investors should monitor ARCpoint’s SEDAR+ profile and other official channels for ongoing information.
Regulatory Differences Between MCTO and FFCTO
The announcement clarifies that an MCTO restricts trading only by certain management and insiders, allowing other shareholders to trade normally under some conditions. In contrast, an FFCTO imposes a comprehensive trading suspension on all persons, including retail and institutional investors, until filings are complete and the order is revoked. This represents a significantly stricter regulatory measure.
Company’s Insolvency Status and Creditor Communication
ARCpoint confirmed it is not currently subject to insolvency proceedings, an important factor for creditors and investors evaluating the company’s financial health and recovery prospects once funding is secured.
The company also committed to filing material change reports on SEDAR+ if it provides any information to creditors during the filing default period, ensuring transparency and compliance with disclosure requirements.
About ARCpoint and Market Environment
ARCpoint Inc. develops MAPL, a multi-tenant software platform for clinical lab ordering, scheduling, and results delivery, serving laboratories and healthcare providers in the United States. Its Class A Subordinate Voting Shares trade on the TSX Venture Exchange under the symbol "ARC." The disclosed regulatory challenges come amid recent market volatility, which may affect the company’s ability to secure funding and influence its securities’ valuation.
Forward-Looking Statements and Risk Factors
The announcement contains forward-looking statements about ARCpoint’s expectation to miss the July 29 filing deadline, the likely issuance of an FFCTO, and ongoing funding efforts. The company acknowledges risks including potential failure to secure financing, inability to file on time or at all, the impact of an FFCTO trading suspension, and adverse effects from market volatility on fundraising and operations.
Ongoing Regulatory Compliance and Disclosure
ARCpoint has pledged to continue issuing updates as required by Canadian securities laws during the filing default period. The company’s commitment to transparency and regulatory compliance will be closely monitored by the BCSC and market participants as the situation evolves.
